Viewing Study NCT00051220


Ignite Creation Date: 2025-12-25 @ 4:27 AM
Ignite Modification Date: 2026-02-26 @ 11:17 PM
Study NCT ID: NCT00051220
Status: COMPLETED
Last Update Posted: 2013-06-07
First Post: 2003-01-07
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Treatment for Specific Phobias in Children
Sponsor: Virginia Polytechnic Institute and State University
Organization:

Study Overview

Official Title: One-Session Treatment for Specific Phobias in Children
Status: COMPLETED
Status Verified Date: 2013-06
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: This study will compare the effectiveness of three treatments in reducing symptoms of phobia in children and adolescents.
Detailed Description: Children with specific phobias may experience academic, social, and personal distress, as well as interference in day-to-day activities. One-Session Treatment has been found a rapid and effective treatment for adults with phobic disorders. However, its utility in the treatment of childhood phobia has not been examined.

Participants are randomly assigned to 1 of 3 groups: a one-session treatment group, an education/support group, and a waitlist control group. The one-session treatment group is directly exposed to a phobia object or situation during a 3-hour treatment session. In the education/support group, children are given information about fear and phobias and are taught how to deal with them through workbook activities. Children who participate in the one-session treatment group or the education/support group are assessed 1 week post-treatment and again after 6 months. Participants with improved symptoms have a 1-year follow-up. Participants with phobias that persist at 6 months are encouraged to participate in alternative treatment. Waitlist control participants are assessed pre-treatment and 1 month post-treatment. Those who continue to have phobias at the 1-month assessment are randomly assigned to 1 of the 2 active treatments.

Study Oversight

Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:

Secondary ID Infos

Secondary ID Type Domain Link View
R01MH059308 NIH None https://reporter.nih.gov/quic… View
DSIR CT-S None None View